CONTEXT: Type 2 familial partial lipodystrophy (FPLD) is an autosomal-dominant lamin A/C-related disease associated with exercise intolerance, muscular pain, and insulin resistance. The symptoms may all be explained by defective metabolism; however, metabolism at the tissue level has not been investigated. OBJECTIVE: We hypothesized that in FPLD, insulin resistance and impaired aerobic exercise capacity are explained by a common underlying mechanism, presumably a muscular metabolic defect. PATIENTS AND METHODS: Carbohydrate and lipid metabolism was studied on 10 FPLD patients, one patient with limb-girdle muscular dystrophy (LGMD1B, a different lamin A/C disease), and 10 healthy control subjects before and during an oral glucose tolerance test by indirect calorimetry and im microdialysis. Muscle biopsies were taken for in vitro studies. RESULTS: We observed marked increased skeletal muscle fatty acid beta-oxidation rate in vitro and in vivo, even after glucose ingestion in FPLD patients. However, fatty acid oxidation was largely incomplete and accompanied by increased ketogenesis. The lipid oxidation abnormality was associated with impaired glucose disposition through reduction in glucose oxidation, rather than decreased cellular glucose uptake. A microarray showed down-regulation of complex I respiratory chain, glycolysis, and nuclear transport genes. Although not overtly insulin resistant, the LGMD1B patient showed similar metabolic derangements as the FPLD patients. CONCLUSIONS: Our study suggests imbalance between lipid oxidation and oxidative glucose metabolism in FPLD and LGMD1B patients. The observation suggests an intrinsic defect in skeletal muscle metabolism due to lamin A/C dysfunction. The metabolic FPLD phenotype likely results from this intrinsic defect combined with lipodystrophic "lipid pressure" due to decreased adipose tissue lipid storage capacity.
CONTEXT: Type 2 familial partial lipodystrophy (FPLD) is an autosomal-dominant lamin A/C-related disease associated with exercise intolerance, muscular pain, and insulin resistance. The symptoms may all be explained by defective metabolism; however, metabolism at the tissue level has not been investigated. OBJECTIVE: We hypothesized that in FPLD, insulin resistance and impaired aerobic exercise capacity are explained by a common underlying mechanism, presumably a muscular metabolic defect. PATIENTS AND METHODS: Carbohydrate and lipid metabolism was studied on 10 FPLD patients, one patient with limb-girdle muscular dystrophy (LGMD1B, a different lamin A/C disease), and 10 healthy control subjects before and during an oral glucose tolerance test by indirect calorimetry and im microdialysis. Muscle biopsies were taken for in vitro studies. RESULTS: We observed marked increased skeletal muscle fatty acid beta-oxidation rate in vitro and in vivo, even after glucose ingestion in FPLD patients. However, fatty acid oxidation was largely incomplete and accompanied by increased ketogenesis. The lipid oxidation abnormality was associated with impaired glucose disposition through reduction in glucose oxidation, rather than decreased cellular glucose uptake. A microarray showed down-regulation of complex I respiratory chain, glycolysis, and nuclear transport genes. Although not overtly insulin resistant, the LGMD1B patient showed similar metabolic derangements as the FPLD patients. CONCLUSIONS: Our study suggests imbalance between lipid oxidation and oxidative glucose metabolism in FPLD and LGMD1B patients. The observation suggests an intrinsic defect in skeletal muscle metabolism due to lamin A/C dysfunction. The metabolic FPLD phenotype likely results from this intrinsic defect combined with lipodystrophic "lipid pressure" due to decreased adipose tissue lipid storage capacity.
Authors: Vamsi K Mootha; Cecilia M Lindgren; Karl-Fredrik Eriksson; Aravind Subramanian; Smita Sihag; Joseph Lehar; Pere Puigserver; Emma Carlsson; Martin Ridderstråle; Esa Laurila; Nicholas Houstis; Mark J Daly; Nick Patterson; Jill P Mesirov; Todd R Golub; Pablo Tamayo; Bruce Spiegelman; Eric S Lander; Joel N Hirschhorn; David Altshuler; Leif C Groop Journal: Nat Genet Date: 2003-07 Impact factor: 38.330
Authors: Mary Elizabeth Patti; Atul J Butte; Sarah Crunkhorn; Kenneth Cusi; Rachele Berria; Sangeeta Kashyap; Yoshinori Miyazaki; Isaac Kohane; Maura Costello; Robert Saccone; Edwin J Landaker; Allison B Goldfine; Edward Mun; Ralph DeFronzo; Jean Finlayson; C Ronald Kahn; Lawrence J Mandarino Journal: Proc Natl Acad Sci U S A Date: 2003-06-27 Impact factor: 12.779
Authors: Harjot K Saini-Chohan; Ryan W Mitchell; Frédéric M Vaz; Teresa Zelinski; Grant M Hatch Journal: J Lipid Res Date: 2011-11-07 Impact factor: 5.922
Authors: Madeleen Bosma; Matthijs K C Hesselink; Lauren M Sparks; Silvie Timmers; Maria João Ferraz; Frits Mattijssen; Denis van Beurden; Gert Schaart; Marc H de Baets; Fons K Verheyen; Sander Kersten; Patrick Schrauwen Journal: Diabetes Date: 2012-07-17 Impact factor: 9.461
Authors: Julia Szendroedi; Albrecht Ingo Schmid; Marek Chmelik; Martin Krssak; Peter Nowotny; Thomas Prikoszovich; Alexandra Kautzky-Willer; Michael Wolzt; Werner Waldhäusl; Michael Roden Journal: PLoS One Date: 2011-07-14 Impact factor: 3.240
Authors: Lauren M Sparks; Cedric Moro; Barbara Ukropcova; Sudip Bajpeyi; Anthony E Civitarese; Matthew W Hulver; G Hege Thoresen; Arild C Rustan; Steven R Smith Journal: PLoS One Date: 2011-07-08 Impact factor: 3.240
Authors: S M R Costa; E Isganaitis; T J Matthews; K Hughes; G Daher; J M Dreyfuss; G A P da Silva; M-E Patti Journal: Int J Obes (Lond) Date: 2016-08-17 Impact factor: 5.095
Authors: Anja Mähler; Jochen Steiniger; Markus Bock; Alexander U Brandt; Verena Haas; Michael Boschmann; Friedemann Paul Journal: PLoS One Date: 2012-08-28 Impact factor: 3.240